Skip to main content
SpringerLink
Log in

Mandatory Reporting Measurements in Trials for Potentially Resectable Pancreatic Cancer

  • Chapter
  • First Online:
Textbook of Pancreatic Cancer

Abstract

Well-defined outcome measures enable comparisons between clinical trials. However, the reporting of baseline and prognostic characteristics largely vary in studies investigating potentially resectable pancreatic cancer patients. This makes accurate comparisons between studies challenging. By standardization of the reporting of mandatory baseline and prognostic characteristics, possible confounders can be identified, which will allow for a better comparison of outcomes across studies. We created a structured overview describing the reporting frequencies of baseline characteristics and the clinical relevance of these factors. This chapter is the first to describe a set of mandatory baseline and prognostic variables for patients with potentially resectable pancreatic cancer.

M.G. Besselink, J.W. Wilmink, and H.W.M. van Laarhoven shared last author.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ter Veer E, van Kleef JJ, Schokker S, van der Woude SO, Laarman M, Haj Mohammad N, et al. Prognostic and predictive factors for overall survival in metastatic oesophagogastric cancer: a systematic review and meta-analysis. Eur J Cancer. 2018;103:214–26.

    Article  PubMed  Google Scholar 

  2. Bradley A, Van der Meer R, McKay CJ. A prognostic Bayesian network that makes personalized predictions of poor prognostic outcome post resection of pancreatic ductal adenocarcinoma. PLoS One. 2019;14(9):e0222270.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Henselmans I, van Laarhoven HWM, de Haes H, Tokat M, Engelhardt EG, van Maarschalkerweerd PEA, et al. Training for medical oncologists on shared decision-making about palliative chemotherapy: a randomized controlled trial. Oncologist. 2019;24(2):259–65.

    Article  PubMed  Google Scholar 

  4. Clark GM. Prognostic factors versus predictive factors: examples from a clinical trial of erlotinib. Mol Oncol. 2008;1(4):406–12.

    Article  PubMed  Google Scholar 

  5. Clark GM, Zborowski DM, Culbertson JL, Whitehead M, Savoie M, Seymour L, et al. Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib. J Thorac Oncol. 2006;1(8):837–46.

    Article  PubMed  Google Scholar 

  6. Le N, Sund M, Vinci A, Pancreas Gcgo. Prognostic and predictive markers in pancreatic adenocarcinoma. Dig Liver Dis. 2016;48(3):223–30.

    Article  CAS  PubMed  Google Scholar 

  7. Leucht S, Chaimani A, Cipriani AS, Davis JM, Furukawa TA, Salanti G. Network meta-analyses should be the highest level of evidence in treatment guidelines. Eur Arch Psychiatry Clin Neurosci. 2016;266(6):477–80.

    Article  PubMed  Google Scholar 

  8. Ter Veer E, van Oijen MGH, van Laarhoven HWM. The use of (network) meta-analysis in clinical oncology. Front Oncol. 2019;9:822.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Ter Veer E, van Rijssen LB, Besselink MG, Mali RMA, Berlin JD, Boeck S, et al. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Lancet Oncol. 2018;19(3):e151–e60.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Bradley A, Van Der Meer R, McKay CJ. A systematic review of methodological quality of model development studies predicting prognostic outcome for resectable pancreatic cancer. BMJ Open. 2019;9(8):e027192.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Lewis RS Jr, Vollmer CM Jr. Risk scores and prognostic models in surgery: pancreas resection as a paradigm. Curr Probl Surg. 2012;49(12):731–95.

    Article  PubMed  Google Scholar 

  12. Abrams RA, Winter KA, Regine WF, Safran H, Hoffman JP, Lustig R, et al. Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704—a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 2012;82(2):809–16.

    Article  CAS  PubMed  Google Scholar 

  13. Caprotti R, Brivio F, Fumagalli L, Nobili C, Degrate L, Lissoni P, et al. Free-from-progression period and overall short preoperative immunotherapy with IL-2 increases the survival of pancreatic cancer patients treated with macroscopically radical surgery. Anticancer Res. 2008;28(3):1951–4.

    CAS  PubMed  Google Scholar 

  14. Casadei R, Di Marco M, Ricci C, Santini D, Serra C, Calculli L, et al. Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which failed to achieve accrual targets. J Gastrointest Surg. 2015;19(10):1802–12.

    Article  PubMed  Google Scholar 

  15. Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–406.

    Article  CAS  PubMed  Google Scholar 

  16. Farnell MB, Pearson RK, Sarr MG, DiMagno EP, Burgart LJ, Dahl TR, et al. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery. 2005;138(4):618–28; discussion 28–30.

    Article  PubMed  Google Scholar 

  17. Gall TM, Jacob J, Frampton AE, Krell J, Kyriakides C, Castellano L, et al. Reduced dissemination of circulating tumor cells with no-touch isolation surgical technique in patients with pancreatic cancer. JAMA Surg. 2014;149(5):482–5.

    Article  PubMed  Google Scholar 

  18. Golcher H, Brunner TB, Witzigmann H, Marti L, Bechstein WO, Bruns C, et al. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther Onkol. 2015;191(1):7–16.

    Article  PubMed  Google Scholar 

  19. Hagiwara Y, Ohashi Y, Uesaka K, Boku N, Fukutomi A, Okamura Y, et al. Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: results from a randomised phase III trial (JASPAC 01). Eur J Cancer. 2018;93:79–88.

    Article  CAS  PubMed  Google Scholar 

  20. Ignjatovic I, Knezevic S, Knezevic D, Dugalic V, Micev M, Matic S, et al. Standard versus extended lymphadenectomy in radical surgical treatment for pancreatic head carcinoma. J BUON. 2017;22(1):232–8.

    PubMed  Google Scholar 

  21. Jang JY, Han Y, Lee H, Kim SW, Kwon W, Lee KH, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg. 2018;268(2):215–22.

    Article  PubMed  Google Scholar 

  22. Jang JY, Kang JS, Han Y, Heo JS, Choi SH, Choi DW, et al. Long-term outcomes and recurrence patterns of standard versus extended pancreatectomy for pancreatic head cancer: a multicenter prospective randomized controlled study. J Hepatobiliary Pancreat Sci. 2017;24(7):426–33.

    Article  PubMed  Google Scholar 

  23. Jang JY, Kang MJ, Heo JS, Choi SH, Choi DW, Park SJ, et al. A prospective randomized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer. Ann Surg. 2014;259(4):656–64.

    Article  PubMed  Google Scholar 

  24. Lygidakis NJ, Sgourakis G, Georgia D, Vlachos L, Raptis S. Regional targeting chemoimmunotherapy in patients undergoing pancreatic resection in an advanced stage of their disease: a prospective randomized study. Ann Surg. 2002;236(6):806–13.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–24.

    Article  CAS  PubMed  Google Scholar 

  26. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073–81.

    Article  CAS  PubMed  Google Scholar 

  27. Nimura Y, Nagino M, Takao S, Takada T, Miyazaki K, Kawarada Y, et al. Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci. 2012;19(3):230–41.

    Article  PubMed  Google Scholar 

  28. Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473–81.

    Article  CAS  PubMed  Google Scholar 

  29. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267–77.

    Article  CAS  PubMed  Google Scholar 

  30. Pal S, Mangla V, Kilambi R, George J, Dash NR, Chattopadhyay TK, et al. An intergroup randomized phase II study of bevacizumab or cetuximab in combination with gemcitabine and in combination with chemoradiation in patients with resected pancreatic carcinoma: a trial of the ECOG-ACRIN Cancer Research Group (E2204). J Surg Oncol. 2018;94(1):39–46.

    Google Scholar 

  31. Regine WF, Winter KA, Abrams R, Safran H, Hoffman JP, Konski A, et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol. 2011;18(5):1319–26.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299(9):1019–26.

    Article  CAS  PubMed  Google Scholar 

  33. Reni M, Balzano G, Aprile G, Cereda S, Passoni P, Zerbi A, et al. Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial. Ann Surg Oncol. 2012;19(7):2256–63.

    Article  PubMed  Google Scholar 

  34. Reni M, Balzano G, Zanon S, Zerbi A, Rimassa L, Castoldi R, et al. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial. Lancet Gastroenterol Hepatol. 2018;3(6):413–23.

    Article  PubMed  Google Scholar 

  35. Schmidt J, Abel U, Debus J, Harig S, Hoffmann K, Herrmann T, et al. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol. 2012;30(33):4077–83.

    Article  CAS  PubMed  Google Scholar 

  36. Shimoda M, Kubota K, Shimizu T, Katoh M. Randomized clinical trial of adjuvant chemotherapy with S-1 versus gemcitabine after pancreatic cancer resection. Br J Surg. 2015;102(7):746–54.

    Article  CAS  PubMed  Google Scholar 

  37. Sinn M, Bahra M, Liersch T, Gellert K, Messmann H, Bechstein W, et al. CONKO-005: adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicenter randomized phase III trial. J Clin Oncol. 2017;35(29):3330–7.

    Article  CAS  PubMed  Google Scholar 

  38. Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009;101(6):908–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388(10041):248–57.

    Article  CAS  PubMed  Google Scholar 

  40. Van Laethem JL, Hammel P, Mornex F, Azria D, Van Tienhoven G, Vergauwe P, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol. 2010;28(29):4450–6.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Yoshitomi H, Togawa A, Kimura F, Ito H, Shimizu H, Yoshidome H, et al. A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer. Cancer. 2008;113(9):2448–56.

    Article  CAS  PubMed  Google Scholar 

  42. Califf RM. Biomarker definitions and their applications. Exp Biol Med (Maywood, NJ). 2018;243(3):213–21.

    Article  CAS  Google Scholar 

  43. Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47–52.

    Article  CAS  PubMed  Google Scholar 

  44. Collisson EA, Bailey P, Chang DK, Biankin AV. Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2019;16(4):207–20.

    Article  PubMed  Google Scholar 

  45. The Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell. 2017;32(2):185–203.e13.

    Article  PubMed Central  Google Scholar 

  46. Aung KL, Fischer SE, Denroche RE, Jang GH, Dodd A, Creighton S, et al. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. Clin Cancer Res. 2018;24(6):1344–54.

    Article  CAS  PubMed  Google Scholar 

  47. Martinez-Useros J, Garcia-Foncillas J. The role of BRCA2 mutation status as diagnostic, predictive, and prognosis biomarker for pancreatic cancer. Biomed Res Int. 2016;2016:1869304.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Holter S, Borgida A, Dodd A, Grant R, Semotiuk K, Hedley D, et al. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol. 2015;33(28):3124–9.

    Article  CAS  PubMed  Google Scholar 

  49. Iqbal J, Ragone A, Lubinski J, Lynch HT, Moller P, Ghadirian P, et al. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2012;107(12):2005–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Furuse J. Paradigm shifting of systemic chemotherapy for unresectable pancreatic cancer in Japan. J Clin Med. 2019;8(8):1170.

    Article  CAS  PubMed Central  Google Scholar 

  51. Navarro EB, López EV, Quijano Y, Caruso R, Ferri V, Durand H, et al. Impact of BRCA1/2 gene mutations on survival of patients with pancreatic cancer: a case-series analysis. Ann Hepatobiliary Pancreat Surg. 2019;23(2):200–5.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Sonnenblick A, Kadouri L, Appelbaum L, Peretz T, Sagi M, Goldberg Y, et al. Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy. Cancer Biol Ther. 2011;12(3):165–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

    E. N. Pijnappel, J. W. Wilmink & H. W. M. van Laarhoven

  2. Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

    J. A. Suurmeijer & Marc G. Besselink

  3. Department of Surgery, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands

    B. Groot Koerkamp

  4. Institute for Developmental Cancer Therapeutics and Division of Solid Tumor Translational Oncology (DKTK partner site Essen), West German Cancer Center, University Hospital Essen, Essen, Germany

    J. T. Siveke

  5. Department of Surgery, Verona University, Verona, Italy

    R. Salvia

  6. Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK

    P. Ghaneh

Authors
  1. E. N. Pijnappel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. A. Suurmeijer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Groot Koerkamp
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. T. Siveke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Salvia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. Ghaneh
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marc G. Besselink
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. W. Wilmink
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H. W. M. van Laarhoven
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. W. M. van Laarhoven .

Editor information

Editors and Affiliations

  1. Stavanger University Hospital, The University of Bergen, Bergen, Norway

    Kjetil Søreide

  2. Chirurgie (VTT), Innsbruck Medical University, Innsbruck, Tirol, Austria

    Stefan Stättner

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Pijnappel, E.N. et al. (2021). Mandatory Reporting Measurements in Trials for Potentially Resectable Pancreatic Cancer. In: Søreide, K., Stättner, S. (eds) Textbook of Pancreatic Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-53786-9_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-53786-9_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-53785-2

  • Online ISBN: 978-3-030-53786-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation